Research programme: angiogenesis inhibitors - Bausch & Lomb/PTC Therapeutics

Drug Profile

Research programme: angiogenesis inhibitors - Bausch & Lomb/PTC Therapeutics

Alternative Names: Research programme: eye disorders therapy - Bausch & Lomb/PTC Therapeutics

Latest Information Update: 27 Jul 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PTC Therapeutics
  • Class Small molecules
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Macular degeneration

Most Recent Events

  • 27 Oct 2007 Bausch and Lomb has been acquired by Warburg Pincus
  • 12 Dec 2005 Preclinical trials in Macular degeneration in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top